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Background: In spite of advances in many noninvasive instruments for studying 
cardiac anomalies in children, cardiac catheterization (CC) is still an essential 
method for the precise calculation of cardiovascular hemodynamic status and for 
performing therapeutic interventions. Accordingly, all adverse events (AE) related 
to CC are a major concern to pediatric cardiologists.
Patients and Methods: A total of 220 children with congenital heart disease (CHD) who 
received cardiac catheterization in our tertiary care hospital between the period of 
January 2000 and December 2002 were studied. One hundred and thirty-eight patients 
were non-cyanotic CHD, 71 were cyanotic CHD and 11 were complex CHD. Diagnostic 
CC was performed in 138 patients and therapeutic CC in 82 patients. All AEs that 
occurred during the CC procedures were identified, recorded and managed at the 
scene. The severities of AE were further classified into minor, obvious and severe.
Results: AEs were observed in 41 patients, including 22 (10%) minor, 16 (7.27%) obvi-
ous and 3 (1.36%) severe AEs. The three severe AEs were cardiac tamponade, severe 
ventricular tachycardia and marked hypoxia-and-bradycardia. None of the patients 
died. Therapeutic CC did not present a higher incidence of AE occurrence than diag-
nostic CC. However, a young age (p < 0.0001), low body weight (p < 0.0001) and cyan-
otic or complex CHD (p = 0.01) appeared to be risk factors for obvious and severe AE.
Conclusion: Although the complication of severe AE during CC may not be totally 
preventable, it is important to be aware of every early sign of AE and to initiate an 
effective intervention by a well trained resuscitation team.
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1. Introduction
With improvements in echocardiography, the role 
of cardiac catheterization (CC) in investigating 
congenital heart disease (CHD) has been re-directed 
to either making a precise hemodynamic study, or 
implement some interventional procedures. 
However, CC-associated complications including 
arrhythmia, massive bleeding, heart perforation, 
cardiac tamponade, thromboembolism, shock, 
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hypoxemia and vessel occlusion remain a major 
concern for performing the procedure.
The complication rate of diagnostic CC is ap-
proximately 0.8%, and those serious complications 
requiring emergent surgical interventions are only 
0.08%−0.6%.1−4 However, the complication rate can 
be as high as 4% to 8% in children’s interventional 
CC.4−11 This finding is well documented in Vitiello 
et al’s series of 4,500 pediatric CCs in 10 years (2.1% 
major complications, 9.3% minor complications and 
0.14% CC-related mortality).8
It is occasionally difficult to distinguish an un-
expected CC-related adverse reaction from a true 
complication. In this study, we attempted to enroll 
patients with all types of unexpected events iden-
tified during CC for analysis regardless of the se-
verity of the adverse event (AE). Therefore, we 
choose to use the term “adverse event” rather than 
“complication”, to better reflect and to describe 
all CC-related events.
2. Methods and Patients
A total of 220 children with CHD who received car-
diac catheterization in our tertiary care hospital 
between the period of January 2000 and December 
2002 were studied. Among those patients, 138 pa-
tients received diagnostic CC and 82 patients 
received therapeutic CC. Their median age was 
15-months-old and their median body weight was 
9.5 kg. All CCs were performed by one pediatric cardi-
ologist and one in-training cardiologic fellow doc-
tor. All of the relevant medical records, CC reports, 
medications and interventions were reviewed by 
one pediatric cardiologist.
2.1. Catheterization technique
For diagnostic CC, patients were sedated by intra-
venous infusion of combined drugs of midazolam 
(0.1 mg/kg/dose), demerol (0.5−1 mg/kg/dose) and 
ketamine (1 mg/kg/dose). For therapeutic CC, pa-
tients were put under general anesthesia. Heparin 
sodium at doses of 50−100 U/kg were administered 
intravenously at the beginning of interventional 
CC, and followed with bolus heparin injections to 
maintain the patient’s hourly activated clotting time 
above 200 seconds. Carbon dioxide inflated balloon 
catheters (Berman Angiographic Balloon Catheter; 
Arrow International Inc., Reading, PA, USA) were 
used in most diagnostic CCs. Dilatation balloon 
catheters with inflation pressures of 3 to 8 atmos-
pheres were used to dilate the obstructed valves 
or vessels. Gianturco coils were used to embolize 
small-to-medium size patent ductus arteriosus. An 
Amplatzer septal occluder or CardioSEAL (NMT 
Medical, Inc., Boston, MA, USA) device was used to 
occlude atrial septal defects. Non-ionized contrast 
media was used for each cineangiogram and the 
dosage was kept between 0.8 to 1.3 mL/kg with 
the total dosage not exceeding 6 mL/kg. Cefazolin 
(40 mg/kg) was administered intravenously as pro-
phylactic antibiotics both before and after the CC 
procedures. Fluoroscopic time of each examina-
tion was recorded automatically by the CC system. 
Procedure time was defined as the period between 
entering and leaving the CC laboratory.
2.2. Demographic data
According to their cardiac anomalies, the 220 pa-
tients were grouped into three groups: non-cyan-
otic CHD (138 patients, 64.5%, including ventricular 
septal defects, coarctation of the aorta, atrial sep-
tal defects, etc.), cyanotic CHD (71 patients, 30.5%, 
including tetralogy of Fallot, transposition of the 
great arteries, double outlet right ventricle, etc.) 
and complex CHD (11 patients, 5%, mainly asplenia 
syndrome).
2.3. Definition of AEs
CC procedures were completed uneventfully in 179 
patients and were defined as the non-AE group. 
The remaining 41 patients suffered different se-
verities of AEs and were defined as the AE group.
The severities of AE were classified into three 
groups: (1) minor AE (unexpected but displayed 
transient hypoxia or arrhythmia, which reverted to 
normal spontaneously without any intervention); 
(2) obvious AE (significant hypoxia, hypotension or 
paleness prompting intervention such as drug infu-
sion, O2 inhalation, mask-and-ambu bagging or blood 
transfusion); (3) severe AE (life threatening events 
requiring cardiopulmonary resuscitation and/or 
emergent surgical interventions).
Age, body weight, cardiac defects (non-cyanotic, 
cyanotic or complex heart disease), and modes of 
CC procedure (diagnostic or therapeutic) were 
compared between the AE and the non-AE groups, 
as well as between the pooled groups of obvious or 
severe AE groups and the non-AE or minor AE 
groups to further elucidate the risk factors associ-
ated with different severities of AE.
3. Results
The underlying three categories of cardiac anoma-
lies of the 138 patients who received diagnostic 
CC were non-cyanotic CHD (88 patients; 63.8%), 
cyanotic CHD (39 patients; 28.3%) and complex 
CHD (11 patients; 8.0%). The underlying cardiac 
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anomalies of the 82 patients who received thera-
peutic CC were non-cyanotic CHD (50 patients; 
60.9%) and cyanotic CHD (32 patients; 39.1%).
Therapeutic CC procedures performed on the 82 
patients consisted of six different procedures as fol-
lows: (1) 29 (35.4%) patients had coil embolizations 
for patent ductus arteriosus, major aortopulmo-
nary collateral arteries and Blalock-Thomas-Taussig 
shunt, (2) 11 (13.4%) patients received septal oc-
cluder procedures for atrial septal defect, (3) 36 
(43.9%) patients received balloon valvuloplasty 
procedures for valvular pulmonary stenosis or aor-
tic stenosis, (4) 4 (4.9%) patients who had transpo-
sition of the great arteries received balloon 
atrioseptostomy procedures, (5) 1 (1.2%) patient 
had temporary pacing lead insertion for complete 
heart block, and (6) 1 (1.2%) patient had an en-
domyocardial biopsy procedure.
AEs occurred in 41 of the total 220 patients 
(18.6%), including 25 out of 138 diagnostic CC (18.1%) 
and 16 out of 82 therapeutic CC (19.5%, Table 1). 
These AEs were further classified into three catego-
ries (minor, obvious and severe) according to the se-
verities of AE. In the diagnostic CC group, the 
distributions of cases in the minor, obvious and se-
vere categories were 15, 9 and 1, respectively, while 
the therapeutic CC group cases had a distribution of 
7, 7 and 2, respectively. Obvi ous AE occurred in 7.2% 
of cases among the total 220 CC procedures, while 
severe AE occurred in 1.4% of the cases.
All different kinds of AE were categorized into 
four groups as follows. Group 1—arrhythmias: 20 
patients (9.1%) with symptoms including transient 
bradycardia, 1st to 3rd degree of atrioventricular block, 
atrial flutter, paroxysmal supraventricular tachy-
cardia and ventricular tachycardia. Group 2—
hypoxia: 10 patients (4.6%) with symptoms ranging 
from transient oxygen desaturation to remarkable 
apnea and bradycardia requiring cardiopulmonary 
resuscitation and even endotracheal intubation. 
Group 3—bleeding: Five patients (2.3%) who suf-
fered significant bleeding at the puncture sites 
and required blood transfusion. Group 4—miscella-
neous: Six patients (2.8%) with symptoms including 
hypothermia, carbon dioxide retention and cardiac 
tamponade.
3.1 Three cases who suffered from severe AE
The first case was a 17-day-old, 2.5 kg male new-
born with severe pulmonary valvular stenosis whose 
right ventricle outflow tract was accidentally per-
forated by a guide wire. Cardiac tamponade then 
occurred and was managed emergently with nee-
dle pericardiocentesis. The bleeding stopped spon-
taneously. The newborn received a right ventricular 
outflow tract reconstruction the next day.
The second case was a 2-month-old, 3.6 kg in-
fant with pulmonary atresia with an intact ven-
tricular septum whose atretic pulmonary valve was 
perforated and dilated by a radiofrequency wire 
and a dilatation balloon catheter a few days after 
birth. This 2nd CC was placed to re-dilate residual 
pulmonary stenosis of a moderate degree. Unex-
pectedly, a severe ventricular tachycardia with shock 
occurred when we attempted to place a JR cathe-
ter across the stenotic pulmonary valve. The arrhyth-
mia was finally converted by electric cardioversion 
and lidocaine infusion.
The third case was a 12-month-old, 9.8 kg infant 
with a large ventricular septal defect and severe pul-
monary hypertension. She appeared very resistant to 
the usual dose of sedatives and eventually she re-
ceived two doses of midazolam (0.1 mg/kg), keta-
mine (1 mg/kg) and demerol (0.5 mg/kg) injections. 
Apnea, cyanosis and bradycardia rapidly occurred 
and cardiopulmonary resuscitation was started; she 
was then revived after 1 minute of cardiac massage.
3.2 Risk factors for AE
The mean age and body weight of the 41 AE-suffering 
patients and 179 non-AE patients are presented in 
Table 1, respectively.
Furthermore, those with obvious AE and those 
with severe AE, together termed significant AE, 
showed significantly different mean age and body 
weight from the rest of the patients (Table 2).
Table 1 Risk factors associated with adverse events (AE)
 AE (n = 41) Non-AE (n = 179) p OR CI
Age (mo) 14.26 ± 20.35 43.82 ± 56.44 < 0.0001 0.97 0.96, 0.99
Body weight (kg) 7.72 ± 6.00 14.95 ± 12.91 < 0.0001 0.91 0.85, 0.96
Procedure time (min) 164.88 ± 80.24 118.73 ± 66.57 < 0.0001 1.01 1.004, 1.01
Fluoroscopic time (min) 30.37 ± 23.29 23.37 ± 19.58 0.035 1.02  1.00, 1.03
Diagnostic CC 25 113 0.7971 0.91 0.45, 1.83
Therapeutic CC 16 66   
OR = odds ratio; CI = confidence interval; CC = cardiac catherterization.
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AE patients also required a significantly longer 
procedure time than non-AE patients (164.9 ± 80.2 
vs. 118.7 ± 66.6 minutes, p < 0.0001, Table 1), and 
this difference was still significant when those with 
significant AE were pooled together to compare with 
the minor and non-AE patients (172.6 ± 86.4 vs. 
123.1 ± 68.6 minutes, p = 0.008, Table 2). Fluoroscopic 
time was slightly longer in the AE group as compared 
to the non-AE group (30.4 ± 23.3 vs. 23.4 ± 19.6 min-
utes, p = 0.035, Table 1).
When occurrence of AE was compared between 
the different categories of cardiac anomalies includ-
ing non-cyanotic, cyanotic and complex CHD, both 
the cyanotic and complex CHD groups were found 
to have  a higher incidence of AE (26.8% and 36.4%) 
than the non-cyanotic group (13%, p = 0.02, odds 
ratio 2.4 and 3.8, respectively, Table 3).The occur-
rences of AE for the combined group of cyanotic 
and complex CHD patients were still significantly 
higher than those of the non-cyanotic patients 
(28% vs. 13%, p = 0.01, odds ratio 2.6, Table 3).
Patients with either cyanotic or complex CHD 
also presented a higher risk for the occurrences of 
significant AEs (12.7% and 27.3%, respectively) than 
those with non-cyanotic CHD (5.1%, p = 0.01, odds 
ratio 2.7 and 7.0, respectively, Table 4). The occur-
rences of significant AEs for the combined group of 
cyanotic and complex CHD patients were still signifi-
cantly higher than those of the non-cyanotic patients 
(14.6% vs. 5.1%, p = 0.03, odds ratio 3.2, Table 4).
4. Discussion
This 3-year study of pediatric CC found that there 
was an 18.6% incidence of all types of AE, including 
Table 2 Risk factors associated with obvious and severe adverse events (AEs)
 Obvious + severe AE (n = 19) Minor + non-AE (n = 201) p OR CI
Age (mo) 8.16 ± 10.93 41.17 ± 54.4 < 0.001 0.94 0.90, 0.99
Body weight (kg) 6.21 ± 4.40 14.31 ± 12.52 < 0.001 0.85 0.75, 0.96
Procedure time (min) 172.63 ± 86.42 123.05 ± 68.57 0.008 1.01 1.002, 1.01
Fluoroscopic time (min) 31.70 ± 23.11 24.03 ± 20.12 0.12 1.02 0.996, 1.04
Diagnostic CC 10 128 0.48 0.65 0.25, 1.63
Therapeutic CC  9  73   
OR = odds ratio; CI = confidence interval; CC = cardiac catherization.
Table 3 Risk for adverse event (AE) occurrences in cyanotic and complex coronary heart disease (CHD) as com-
pare to the non-cyanotic CHD
 AE Non-AE OR 95% Wald CL p
Non-cyanotic 18 (13.0%) 120 (87.0%) 1.00  − −
Cyanotic 19 (26.8%)  52 (73.2%) 2.44  1.18−5.02  0.02
Complex   4 (36.4%)  7 (63.6%) 3.81  1.01−14.33  0.02
Cyanotic + complex 23 (28.0%)  59 (72.0%) 2.60 1.30−5.19  0.01
OR = odds ratio; CL = confidence limits.
Table 4 Risk for obvious and severe adverse event (AE) occurrences in cyanotic or complex coronary heart disease 
(CHD) as compare to non-cyanotic CHD
 Obvious + Severe AE Minor AE + Non-AE OR 95% Wald CL p
Non-cyanotic 7 (5.1%) 131 (94.9%) 1.00  − −
Cyanotic   9 (12.7%)  62 (87.3%) 2.72 0.97−7.63  0.01
Complex   3 (27.3%)  8 (72.7%) 7.02 1.52−32.39 0.01
Cyanotic + complex 12 (14.6%)  70 (85.4%) 3.21 1.21−8.52  0.03
OR = odds ratio; CL = confidence limits.
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8.6% of obvious and severe AE. These data are con-
sistent with previous reports in pediatric CC.4,8−11 
In addition, patients who received therapeutic CC in 
this study had a higher risk for occurrence of AE 
than those who received diagnostic CC, for all se-
verities of AE (Tables 1 and 2). Moreover,  young 
age, low body weight and cyanotic or complex CHD 
(26.8%, 36.4% vs. 13%, p = 0.02) are major risk fac-
tors for AE occurrence (Tables 1 and 3). Our results 
showed that the more severe the AE, the longer 
the procedure time is required (Tables 1 and 2). 
However, the cause-and-effect relationship is not 
clear.
Since all minor AE events revert to normal spon-
taneously, it seems reasonable to consider only the 
obvious and severe AE as significant AE and the pa-
tients who have non-AE and minor AE as controls 
(Table 4). We showed that cyanotic or complex CHD 
is a risk factor for the occurrence of significant AE, 
as compared to the patients with simple CHD, for 
all degrees of AE severity (Tables 3 and 4).
Fortunately, in spite of the 8.6% occurrence 
rate of obvious or severe AE in this study, no deaths 
occurred. This emphasizes the importance of an 
efficient resuscitation team be set up in the cath-
eterization laboratory and this team should be 
capable of detecting all types of AE at the earliest 
stage, as well as be able to implement necessary 
interventions in patients without delay. In addi-
tion, a backup team of cardiac surgeons needs 
to be prepared for emergent interventions when 
required.
Severe AE requiring resuscitation occurred in 
three patients in this study; 2 in therapeutic CC 
and one in diagnostic CC. These results illustrate 
that not only therapeutic CC, but a young-age for 
diagnostic CC, are risk factors for occurrence of 
severe AE. In order for the members of the cathe-
ter laboratory team to be familiar with the com-
mon AE, we have described their presenting signs 
and symptoms and specific managing strategies as 
follows. Arrhythmias ranked the highest incidence 
of AE in this study, which is consistent with other 
reports.12,13 They include sinus bradycardia, vari-
ous degrees of atrioventricular block, atrial flutter, 
paroxysmal supraventricular tachycardia and ven-
tricular tachycardia. Most arrhythmias are associ-
ated with inadvertently probing or compressing on 
the myocardium or conduction tissue, so it is more 
prudent and safer to use as much balloon-tipped 
soft catheters as possible rather than the stiff-end 
catheters in most CC procedures. It is advisable to 
be very cautious to not probe the areas of conduc-
tion tissue, such as the lower superior vena cava and 
the atrioventricular node, and areas involved in the 
arrhythmia pathways, such as the pulmonary venous 
orifices. Moreover, patients with l- or d-transposition 
of the great arteries, tetralogy of Fallot and pre-
existing bifascicular block are also high-risk for 
complete atrioventricular block.
Hypoventilation, apnea, oxygen desaturation 
or even bradycardia requiring cardiopulmonary 
resuscitation and/or endotracheal intubation oc-
curred in 10 of our 220 CC patients (4.6%). Hypoxemia 
was documented by pulse oximeters in all cases. 
Risk factors for hypoventilation are sedative drugs, 
physical restraint, congenital airway anomalies, 
gastroesophageal reflux, high pulmonary vascular re-
sistance, jugular or subclavian venous puncture, 
Down’s syndrome with a short chin and large tongue, 
and newborns undergoing prostaglandin infusion. 
Although most diagnostic CCs can be performed 
safely under proper intravenous sedation, high-risk 
patients should have pre-catheter consultations and 
thorough communication with the anesthesiologist 
to be well prepared.
Blue spells or hypoxic spells can appear in pa-
tients with tetralogy of Fallot and can be a life 
threatening event, which occurred in one of our 
CC patients during the procedure. In addition to 
reducing all kinds of stimulations in the patient as 
much as possible, we also make it routine practice 
to give the patient another dose of oral propranolol 
4−6 hours before the CC.
Paroxysmal pulmonary artery hypertension cri-
sis (PPHC), which occurs in patients with long term 
pulmonary arterial hypertension, can be another 
life-threatening complication during CC; this oc-
curred in two of our patients. When it occurs, the 
patient may be overtaken by a cascade of cyano-
sis, hypotension and bradycardia in minutes, and it 
is crucially important to reduce all types of stimu-
lations in high-risk patients; there may even be a 
need to have someone on standby when tracheal 
intubation is necessary. Furthermore, inhalation 
nitric oxide is the only specific therapy for PPHC 
attacks and it should always be available in the 
catheterization laboratory.14−18
Cardiac perforation with cardiac tamponade is 
the worst situation for all interventional cardiolo-
gists. This complication is always the first one to 
be ruled out whenever hypotension suddenly oc-
curs during CC. The diagnosis can be confirmed by 
either fluoroscope or echocardiography. In addition, 
an emergent needle pericardiocentesis to drain off 
bloody pericardial fluid should be performed by 
the operating cardiologist without delay, as well as 
cardiopulmonary resuscitation. In the case of a large 
volume of bleeding, the cardiac surgeon needs to 
be summoned urgently to create a pericardial 
window.
When hypothermia (≤ 35ºC) occurs in a small in-
fant for long time, it may cause low cardiac output. 
Three of our patients showed hypothermia during CC. 
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Fortunately their cardiac outputs were well main-
tained. Therefore, a small infant should be kept warm 
throughout CC with a heating lamp or blanket if a 
prolonged CC is unavoidable.
Femoral vessel injury was documented in three 
of our patients by angiograms or CT scans. The first 
patient was a 4-day-old newborn who received 
femoral arterial cut-down for performing a balloon 
angioplasty of the coarctation of aorta. The femo-
ral artery occlusion was documented by 2nd CC at 
11 months of age. The other two patients, 7 months 
and 4 years of age, were thought to have their 
femoral veins injured during device retrieving pro-
cedures when an 8 mm Gianturco coil and a 28 mm 
CardioSEAL device, respectively, were pulled out 
forcefully from their femoral veins. Femoral arte-
rial injuries after pediatric CC include bleeding, he-
matoma, pseudoaneurysm, arteriovenous fistula, 
thrombosis and occlusion. The incidence of femo-
ral arterial injuries can be as high as 40% in young 
patients less than 10-years-old. Its risk factors in-
clude young age, surgical cut down, use of large bore 
catheters, interventional catheterization, low car-
diac output, dehydration and polycythemia.20 
Femoral anterial injuries should be suspected 
whenever a leg becomes cool and pulseless after a 
CC. It has been recommended that high dose (50 
units/kg) heparin be given to patients younger 
than 10 years of age prior to CC as a preventive 
measure. In case of a femoral artery injury, it 
should be managed with continuous infusion of 
heparin and thrombolytic agents such as streptoki-
nase or urokinase. A surgical embolectomy may 
even be required to save the ischemic limb.19,20
5. Conclusion
AE can occur throughout the entire course of CC 
procedures, from premedication for sedation, ves-
sel puncture, and diagnostic catheterizations to 
therapeutic interventions. The catheterization team 
needs to be familiar with all types of AE and their 
specific management protocols so that early rec-
ognition and early intervention can be accom-
plished. This study showed that a young age, lower 
body weight and cyanotic or complex CHD are risk 
factors for occurrence of AE. Although therapeutic 
CC appears to have a higher risk for AE than that of 
diagnostic CC, the difference is not statistically 
significant in pediatric CC.
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